SCHEMBL4425201

SCHEMBL4425201

CC(Nc1nc(Nc2cn(C)cn2)nc(N2CCOCC2)n1)c1ccc(C#N)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
ALDH1A1 P00352 2/20 0.41
CTSL P07711 6/20 0.40
CTSK P43235 6/20 0.40
CTSS P25774 5/20 0.40
CTSB P07858 5/20 0.40
KDM4E B2RXH2 2/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
LMNA P02545 4/20 0.39
MAPK1 P28482 1/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2161754 1.00 MAPT (0.41) MAPTALDH1A1CTSLCTSKCTSS
SCHEMBL1396501 0.88 MAPT (0.53) MAPTALDH1A1CTSLCTSKCTSS
SCHEMBL2161164 0.88 MAPT (0.53) MAPTALDH1A1CTSLCTSKCTSS
SCHEMBL2162078 0.88 LMNA (0.46) MAPTALDH1A1KDM4EGLAGAA
SCHEMBL4424451 0.83 JAK2 (0.41) IDH1JAK2
SCHEMBL2160830 0.83 JAK2 (0.41) IDH1JAK2
SCHEMBL2160983 0.78 JAK2 (0.57) JAK2
SCHEMBL2160773 0.75 JAK2 (0.53) MAPTJAK2
SCHEMBL1396349 0.75 JAK2 (0.53) MAPTJAK2
SCHEMBL2161322 0.75 JAK2 (0.53) MAPTJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009150462-A1 TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2009-12-17 WO disclosed